Qube Research & Technologies LTD Black Diamond Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $61.9 Billion
- Q1 2024
A detailed history of Qube Research & Technologies LTD transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 172,629 shares of BDTX stock, worth $825,166. This represents 0.0% of its overall portfolio holdings.
Number of Shares
172,629
Previous 46,710
269.58%
Holding current value
$825,166
Previous $131,000
567.94%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BDTX
# of Institutions
93Shares Held
36.5MCall Options Held
29.6KPut Options Held
5K-
Bellevue Group Ag Kuesnacht, V88.52MShares$40.7 Million0.68% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$32.1 Million0.02% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$21.3 Million1.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.91MShares$9.11 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.6MShares$7.66 Million0.99% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $174M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...